US2022105180A1PendingUtilityA1
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
Est. expiryJul 15, 2034(~8 yrs left)· nominal 20-yr term from priority
Inventors:Melissa Junttila
A61K 39/395A61K 39/39558A61K 31/4523C07K 2317/52A61K 2039/542C07K 2317/73C07K 2317/72A61P 35/00C07K 2317/56C07K 2317/76A61K 2300/00C07K 16/2827A61K 39/3955A61P 35/04C07K 16/2803A61K 45/06A61K 2039/505A61P 43/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
Claims
exact text as granted — not AI-modified1 - 53 . (canceled)
54 . A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and a MEK inhibitor, wherein the individual has not been previously treated with a B-raf antagonist, and wherein the individual has cancer that is at risk of developing resistance to the B-raf antagonist.Join the waitlist — get patent alerts
Track US2022105180A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.